Retatrutide vs Mounjaro (tirzepatide): what the evidence compares
Retatrutide and Mounjaro are not interchangeable: retatrutide is an investigational GIP, GLP-1 and glucagon receptor agonist, while Mounjaro contains tirzepatide, a GIP and GLP-1 receptor agonist authorised in the EU. Phase 2 retatrutide studies and tirzepatide product information answer different questions. A registered Phase 3 comparison is a study design, not a result or proof of superiority.
Published: · Last reviewed:
Evidence summary, not medical advice. Retatrutide is investigational. Any research product is not a medicine and is not for human use.
Related research reading
Three receptor targets versus two
Peer-reviewed studies describe retatrutide as acting at GIP, GLP-1 and glucagon receptors. EMA product information describes tirzepatide in Mounjaro as acting at GIP and GLP-1 receptors. These are pharmacological descriptions; receptor count alone does not establish comparative benefit, safety or suitability.
Different regulatory positions
Mounjaro has an EU marketing authorisation, with the authorised uses set out in the current EMA product information. Lilly describes retatrutide as investigational and reports Phase 3 programme updates, including sponsor-announced topline findings in May and July 2026. Those announcements are not peer-reviewed publications or marketing authorisation. Lilly’s overview: https://www.lilly.com/news/stories/what-to-know-about-retatrutide
What the study designs can—and cannot—show
The published retatrutide obesity Phase 2 trial was randomised, double-blind and placebo-controlled; it was not a comparison with tirzepatide. ClinicalTrials.gov records TRIUMPH-5 as a randomised, double-blind Phase 3 retatrutide-versus-tirzepatide study. Its protocol does not supply comparative outcomes. Until suitable results are publicly reported and assessed, no head-to-head outcome or superiority claim is warranted.
Research references
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial — New England Journal of Medicine / PubMed, PMID 37366315; DOI 10.1056/NEJMoa2301972
- TRIUMPH-1: A Study of Retatrutide in Participants Who Have Obesity or Overweight — ClinicalTrials.gov, NCT05929066
- A Study of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity — ClinicalTrials.gov, NCT06662383; TRIUMPH-5
- Mounjaro: European Public Assessment Report — European Medicines Agency, EMA/EPAR; tirzepatide
Reference questions
Does targeting three receptors mean retatrutide is better?
No. Mechanism is not a comparative clinical outcome. The cited Phase 2 obesity trial compared retatrutide with placebo, not Mounjaro; a registered later comparison is not itself evidence of a result.
Is retatrutide approved like Mounjaro?
No. EMA records Mounjaro as authorised in the EU. Lilly identifies retatrutide as investigational and not approved by a regulatory agency. Regulatory status can vary by jurisdiction and should be checked with the relevant regulator.